-
甲状腺功能减退症(简称甲减)是由于甲状腺激素(thyroid hormones,TH)合成和分泌减少或组织作用减弱而引起的全身代谢减低综合征。约90%以上的原发甲减是由自身免疫性甲状腺疾病、甲状腺手术或甲亢的131I治疗所致[1]。甲减患者常合并血脂异常,特别是血清胆固醇和甘油三酯(triglyceride,TG)水平的升高,血脂异常是导致动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)最主要的危险因素之一。笔者就近年来有关甲减合并胆固醇和TG等血脂异常的研究进展进行综述。
甲状腺功能减退症合并血脂异常的研究进展
Advances in the study of hypothyroidism combined with dyslipidemia
-
摘要: 甲状腺功能减退症(简称甲减)常合并血清胆固醇和甘油三脂水平升高等血脂异常,是动脉粥样硬化性心血管疾病最主要的危险因素之一,严重影响患者的生活和生存质量。笔者就近年来有关甲状腺激素对血脂代谢的调节、临床及亚临床甲减对血脂的影响、甲减合并血脂异常的治疗等的研究进展进行综述,以期为甲减合并血脂异常的防治提供参考。Abstract: Hypothyroidism is often combined with dyslipidemia such as elevated serum cholesterol and triglyceride levels, which is one of the major risk factors for atherosclerotic cardiovascular disease, and seriously affects patients' quality of life and survival. This paper reviews the recent research progress on the regulation of thyroid hormone on lipid metabolism, the effect of hypothyroidism and subclinical hypothyroidism on lipids, and the treatment of hypothyroidism combined with dyslipidemia, in order to provide reference for the prevention and treatment of hypothyroidism combined with dyslipidemia.
-
Key words:
- Hypothyroidism /
- Dyslipidemias /
- Tyroid hormones /
- Levothyroxine
-
[1] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 甲状腺功能减退症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(11): 1022−1028. DOI: 10.3760/cma.j.issn.1671-7368.2019.11.004.
Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of hypothyroidism (2019)[J]. Chin J Gen Pract, 2019, 18(11): 1022−1028. DOI: 10.3760/cma.j.issn.1671-7368.2019.11.004.[2] Yang HX, Zhang M, Long SY, et al. Cholesterol in LDL receptor recycling and degradation[J]. Clin Chim Acta, 2020, 500: 81−86. DOI: 10.1016/j.cca.2019.09.022. [3] Yildirim AM, Koca AO, Beyan E, et al. Association of serum proprotein convertase Subtilisin/Kexin type 9 (PCSK9) level with thyroid function disorders[J]. Eur Rev Med Pharmacol Sci, 2021, 25(17): 5511−5517. DOI: 10.26355/eurrev_202109_26662. [4] Fazaeli M, Khoshdel A, Shafiepour M, et al. The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes[J]. Diabetes Metab Syndr, 2019, 13(1): 312−316. DOI: 10.1016/j.dsx.2018.08.021. [5] Delitala AP, Fanciulli G, Maioli M, et al. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease[J]. Eur J Intern Med, 2017, 38: 17−24. DOI: 10.1016/j.ejim.2016.12.015. [6] Sun C, Liu W, Lu ZQ, et al. Hepatic miR-378 modulates serum cholesterol levels by regulating hepatic bile acid synthesis[J/OL]. Theranostics, 2021, 11(9): 4363−4380[2022-04-01]. https://www.thno.org/v11p4363.htm. DOI: 10.7150/thno.53624. [7] Prieur X, Huby T, Coste H, et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5[J]. J Biol Chem, 2005, 280(30): 27533−27543. DOI: 10.1074/jbc.M503139200. [8] Yang LY, Yin RL, Wang ZW, et al. Circulating Angptl3 and Angptl8 are increased in patients with hypothyroidism[J]. Biomed Res Int, 2019, 2019: 3814687. DOI: 10.1155/2019/3814687. [9] Jin NJ, Matter WF, Michael LF, et al. The angiopoietin-like protein 3 and 8 complex interacts with lipoprotein lipase and induces LPL cleavage[J]. ACS Chem Biol, 2021, 16(3): 457−462. DOI: 10.1021/acschembio.0c00954. [10] Tian LM, Song YF, Xing MZ, et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway[J]. Hepatology, 2010, 52(4): 1401−1409. DOI: 10.1002/hep.23800. [11] Song YF, Xu C, Shao SS, et al. Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis[J]. J Hepatol, 2015, 62(5): 1171−1179. DOI: 10.1016/j.jhep.2014.12.006. [12] Gong YY, Ma YZ, Ye ZQ, et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression[J]. Metabolism, 2017, 76: 32−41. DOI: 10.1016/j.metabol.2017.07.006. [13] Zhou LY, Wu KP, Zhang LY, et al. Liver-specific deletion of TSHR inhibits hepatic lipid accumulation in mice[J]. Biochem Biophys Res Commun, 2018, 497(1): 39−45. DOI: 10.1016/j.bbrc.2018.01.187. [14] Beukhof CM, Massolt ET, Visser TJ, et al. Effects of thyrotropin on peripheral thyroid hormone metabolism and serum lipids[J]. Thyroid, 2018, 28(2): 168−174. DOI: 10.1089/thy.2017.0330. [15] Wang JJ, Zhuang ZH, Shao CL, et al. Assessment of causal association between thyroid function and lipid metabolism: a Mendelian randomization study[J]. Chin Med J (Engl), 2021, 134(9): 1064−1069. DOI: 10.1097/CM9.0000000000001505. [16] Su X, Peng H, Chen X, et al. Hyperlipidemia and hypothyroidism[J]. Clin Chim Acta, 2022, 527: 61−70. DOI: 10.1016/j.cca.2022.01.006. [17] Saif A, Mousa S, Assem M, et al. Endothelial dysfunction and the risk of atherosclerosis in overt and subclinical hypothyroidism[J/OL]. Endocr Connect, 2018, 7(10): 1075−1080[2022-04-01]. https://ec.bioscientifica.com/view/journals/ec/7/10/EC-18-0194.xml. DOI: 10.1530/EC-18-0194. [18] Li HY, Xu Q, Liu J, et al. Detection of blood lipids, homocysteine and endothelin in patients with hypothyroidism and subclinical hypothyroidism and its clinical significance[J]. Am J Clin Exp Med, 2019, 7(1): 31−34. DOI: 10.11648/j.ajcem.20190701.14. [19] van der Boom T, Jia CZ, Lefrandt JD, et al. HDL cholesterol efflux capacity is impaired in severe short-term hypothyroidism despite increased HDL cholesterol[J]. J Clin Endocrinol Metab, 2020, 105(9): e3355−e3362. DOI: 10.1210/clinem/dgaa411. [20] Jung KY, Ahn HY, Han SK, et al. Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function[J]. J Clin Lipidol, 2017, 11(6): 1347−1353. DOI: 10.1016/j.jacl.2017.08.015. [21] Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review[J]. JAMA, 2019, 322(2): 153−160. DOI: 10.1001/jama.2019.9052. [22] Treister-Goltzman Y, Yarza S, Peleg R. Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis[J]. Minerva Endocrinol (Torino), 2021, 46(4): 428−440. DOI: 10.23736/S2724-6507.20.03197-1. [23] Dahl AR, Iqbal AM, Lteif AN, et al. Mild subclinical hypothyroidism is associated with paediatric dyslipidaemia[J]. Clin Endocrinol (Oxf), 2018, 89(3): 330−335. DOI: 10.1111/cen.13752. [24] Janovsky CCPS, Generoso G, Goulart AC, et al. Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: the ELSA-Brasil study[J]. Atherosclerosis, 2020, 312: 60−65. DOI: 10.1016/j.atherosclerosis.2020.08.021. [25] 陈春梅, 刘佳, 贾育梅, 等. 甲状腺功能正常人群血清促甲状腺激素水平与血脂的相关性[J]. 中国心血管杂志, 2020, 25(1): 45−49. DOI: 10.3969/j.issn.1007-5410.2020.01.011.
Chen CM, Liu J, Jia YM, et al. Correlation between serum thyroid-stimulating hormone and blood lipid in subjects with normal thyroid function[J]. Chin J Cardiovasc Med, 2020, 25(1): 45−49. DOI: 10.3969/j.issn.1007-5410.2020.01.011.[26] Liu LX, Liu J F, Fu SB, et al. Correlation between serum TSH levels within normal range and serum lipid profile[J]. Horm Metab Res, 2021, 53(1): 32−40. DOI: 10.1055/a-1191-7953. [27] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019, 73(24): e285−e350. DOI: 10.1016/j.jacc.2018.11.003. [28] Kotwal A, Cortes T, Genere N, et al. Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2020, 105(12): 3683−3694. DOI: 10.1210/clinem/dgaa672. [29] McAninch EA, Rajan KB, Miller CH, et al. Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2018, 103(12): 4533−4542. DOI: 10.1210/jc.2018-01361. [30] Lee YK, Lee H, Han S, et al. Association between thyroid-stimulating hormone level after total thyroidectomy and hypercholesterolemia in female patients with differentiated thyroid cancer: a retrospective study[J/OL]. J Clin Med, 2019, 8(8): 1106[2022-04-01]. https://www.mdpi.com/2077-0383/8/8/1106. DOI: 10.3390/jcm8081106. [31] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(5): 406−416. DOI: 10.3760/cma.j.issn.1671-7368.2019.05.003.
Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of dyslipidemias (2019)[J]. Chin J Gen Pract, 2019, 18(5): 406−416. DOI: 10.3760/cma.j.issn.1671-7368.2019.05.003.[32] Wang YP, Li QH, Yuan ZS, et al. Statin use and benefits of thyroid function: a retrospective cohort study[J/OL]. Front Endocrinol (Lausanne), 2021, 12: 578909[2022-04-01]. https://www.frontiersin.org/articles/10.3389/fendo.2021.578909/full. DOI: 10.3389/fendo.2021.578909. [33] Krysiak R, Szkróbka W, Okopień B. Atorvastatin potentiates the effect of selenomethionine on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis[J]. Curr Med Res Opin, 2019, 35(4): 675−681. DOI: 10.1080/03007995.2018.1541314.
计量
- 文章访问数: 4153
- HTML全文浏览量: 3046
- PDF下载量: 23